Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT
17 May 2022 - 7:00AM
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell
therapy to treat cancer, is presenting preclinical proof-of-concept
data from its second next-generation SPEAR T-cell (ADP-A2M4N7X19)
targeting MAGE-A4, and novel tumor-infiltrating lymphocytes (TILs)
expressing IL-7 (ADP-TILIL7) at the American Society of Gene &
Cell Therapy (ASGCT) annual meeting. The Company is presenting the
two posters today at 5:30 p.m. EDT during the Cell Therapies I and
Targeted Gene and Cell Therapy I sessions.
“We have seen impressive clinical results with our
first-generation product, afami-cel, in sarcoma, and we set a goal
to increase potency to achieve responses in additional
indications,” said Elliot Norry, Adaptimmune’s Chief Medical
Officer. “To that end, we delivered our first next-gen product into
the clinic incorporating CD8 and have shown responses across a
broad range of solid tumor types in our SURPASS program. We have
now presented preclinical data at ASGCT from our second next-gen
therapy designed to improve durability and persistence of SPEAR
T-cells that supports clinical investigation.”
New next-generation SPEAR T-cells show potential for
enhanced clinical activity with improved proliferation, survival,
and infiltration of immune cells into tumors in preclinical
studies
- The Company aimed to enhance
durability and persistence by engineering a new next-gen SPEAR
T-cell targeting MAGE-A4 to secrete IL-7 and CCL19 (ADP-A2M4N7X19)
using “Proliferation-Inducing and Migration- Enhancing” (PRIME)1
technology
- IL-7 stimulates T-cell
proliferation and survival, and CCL19 induces infiltration of
immune cells
- Naturally occurring T-cells do not
express IL-7 or CCL19
- Next-generation ADP-A2M4N7X19 SPEAR
T-cells were shown to produce IL-7 and CCL19 only in the presence
of the MAGE-A4 cancer target
- IL-7 production by ADP-A2M4N7X19 SPEAR T-cells enhanced T-cell
survival, and CCL19 production induced infiltration of immune
cells
- Based on these data, Adaptimmune will initiate a Phase 1
clinical trial with ADP-A2M4N7X19 in multiple solid tumor
indications
TILs engineered to produce IL-7 may result in a more
effective therapy for people with metastatic melanoma with
preclinical data demonstrating enhanced TIL survival
- TIL therapy has shown some of the
most favorable responses in refractory metastatic melanoma2
- Adaptimmune applied their lentiviral technology to TILs
engineering them to express IL-7 (ADP-TILIL7) with the aim to
improve clinical responses
- Data indicate that these engineered TILs produce biologically
relevant amounts of IL-7; a factor that the TILs cannot produce on
their own
- IL-7 is known to support T-cell proliferation and survival,
which may increase clinical activity and durability of T-cells
- Based on these data, a single-center, Phase 1 clinical trial
will be initiated at CCIT in Denmark with ADP-TILIL7 to treat
patients with metastatic melanoma
The Company will also present a poster entitled “A Novel Flow
Cytometry Method for Rapid Assessment of Lentiviral Detection” on
May 19th.
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR (Specific Peptide Enhanced Affinity
Receptor) T-cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Annual Report on Form
10-K filed with the Securities and Exchange Commission for the year
ended December 31, 2021, our Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, and other filings with the Securities
and Exchange Commission. The forward-looking statements contained
in this press release speak only as of the date the statements were
made and we do not undertake any obligation to update such
forward-looking statements to reflect subsequent events or
circumstances.
Adaptimmune Contacts:
Media Relations:
Sébastien Desprez — VP, Corporate Affairs and CommunicationsT:
+44 1235 430 583M: +44 7718 453
176Sebastien.Desprez@adaptimmune.com
Investor Relations:
Juli P. Miller, Ph.D. — VP, Investor RelationsT: +1 215 825
9310M: +1 215 460 8920Juli.Miller@adaptimmune.com
_______________1 PRIME technology used in collaboration with
Noile-Immune Biotech 2 Hulen TM, et al. Immuno. 2021;1(3):194; Muul
LM, et al. J Immunol. 1987;138(3):989
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024